The Role of Matrix Metalloproteinases in the Immunopathology of Cerebral Tuberculosis
Author(s)
Green, Justin Anton
Type
Thesis or dissertation
Abstract
Introduction: Central nervous system tuberculosis (CNS TB) has a high
mortality. Microglial derived matrix metalloproteinases (MMPs) are implicated in
the intense inflammatory response to Mycobacterium tuberculosis (M.tb) as the
blood brain barrier is rich in MMP substrates.
Methods: In a cellular model of CNS TB human microglial cells were stimulated
with M.tb and conditioned media from M.tb infected human monocytes
(CoMTb). Gene expression of all 23 MMPs and the 4 tissue inhibitors of MMP
(TIMPs) was analysed by real time RT-PCR and secretion by Luminex and
Western blotting. MMP gene transcription regulation was studied by luciferase
promoter reporter assays and NFkB/AP-1 ELISAs. MAP kinases were studied
by Western blotting. Immunohistochemistry of CNS TB biopsies and ELISA
analysis of cerebrospinal fluid (CSF) was performed.
Results: CoMTb up-regulated expression of MMP-1, -3 and -9, which was
suppressed by dexamethasone. In contrast CoMTb did not alter TIMP-1 and
reduced TIMP-2, -3 and -4 expression. M.tb up-regulated MMP-1 and -3
secretion. However, CoMTb drove MMP-1 and -3 secretion more potently than
M.tb but suppressed MMP-2 secretion. Nuclear NFkB p50-p65 heterodimers
and AP-1 cJun/FosB increased in CoMTb stimulated cells, with concomitant
degradation of IkBα. Mutation of NFkB and AP-1 sites in the MMP-1 promoter
abrogated CoMTb promoter activity. CoMTb drove early p38 and ERK MAP
kinase phosphorylation. Chemical inhibition of both NFkB and p38 returned
MMP-1 and 3 secretion to control levels but enhanced MMP-2 secretion that
was also caspase 8 dependent. MMP/TIMP concentrations in CSF samples from TBM patients were predictive of coma severity and outcome and
demonstrated that dexamethasone preferentially suppressed MMP-9.
Conclusions: In CNS TB unopposed MMP-1 and -3 expression and secretion
are driven by M.tb-infected monocyte networks and regulated by p38, NFkB and
AP-1. CSF MMP/TIMP concentrations predict disease severity and offer a
mechanism for the beneficial effect of dexamethasone therapy.
mortality. Microglial derived matrix metalloproteinases (MMPs) are implicated in
the intense inflammatory response to Mycobacterium tuberculosis (M.tb) as the
blood brain barrier is rich in MMP substrates.
Methods: In a cellular model of CNS TB human microglial cells were stimulated
with M.tb and conditioned media from M.tb infected human monocytes
(CoMTb). Gene expression of all 23 MMPs and the 4 tissue inhibitors of MMP
(TIMPs) was analysed by real time RT-PCR and secretion by Luminex and
Western blotting. MMP gene transcription regulation was studied by luciferase
promoter reporter assays and NFkB/AP-1 ELISAs. MAP kinases were studied
by Western blotting. Immunohistochemistry of CNS TB biopsies and ELISA
analysis of cerebrospinal fluid (CSF) was performed.
Results: CoMTb up-regulated expression of MMP-1, -3 and -9, which was
suppressed by dexamethasone. In contrast CoMTb did not alter TIMP-1 and
reduced TIMP-2, -3 and -4 expression. M.tb up-regulated MMP-1 and -3
secretion. However, CoMTb drove MMP-1 and -3 secretion more potently than
M.tb but suppressed MMP-2 secretion. Nuclear NFkB p50-p65 heterodimers
and AP-1 cJun/FosB increased in CoMTb stimulated cells, with concomitant
degradation of IkBα. Mutation of NFkB and AP-1 sites in the MMP-1 promoter
abrogated CoMTb promoter activity. CoMTb drove early p38 and ERK MAP
kinase phosphorylation. Chemical inhibition of both NFkB and p38 returned
MMP-1 and 3 secretion to control levels but enhanced MMP-2 secretion that
was also caspase 8 dependent. MMP/TIMP concentrations in CSF samples from TBM patients were predictive of coma severity and outcome and
demonstrated that dexamethasone preferentially suppressed MMP-9.
Conclusions: In CNS TB unopposed MMP-1 and -3 expression and secretion
are driven by M.tb-infected monocyte networks and regulated by p38, NFkB and
AP-1. CSF MMP/TIMP concentrations predict disease severity and offer a
mechanism for the beneficial effect of dexamethasone therapy.
Date Issued
2009
Date Awarded
2009-02
Advisor
Friedland, Jon
Sponsor
James Maxwell Grant Prophit TB Fellowship (RCP), an MRC Clinical Training Fellowship, the Mason Medical Foundation and the Hammersmith Hospital Special Trustees
Creator
Green, Justin Anton
Publisher Department
Infectious Diseases and Immunity
Publisher Institution
Imperial College London
Qualification Level
Doctoral
Qualification Name
Doctor of Philosophy (PhD)